AstraZeneca Acquires Spirogen for Next-Generation Antibody-Drug Conjugate Platform
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 10 (Table of Contents)
Published: 25 Oct-2013
DOI: 10.3833/pdr.v2013.i10.1986 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Consistent with its research focus on antibody-drug conjugates (ADCs) and immune-mediated cancer therapies, AstraZeneca’s MedImmune unit has agreed to acquire Spirogen, a UK biotech majority owned by private equity firm Auven Therapeutics, in a deal worth up to US$440 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS